NASDAQ$GOCO
GoHealth Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
GoHealth's Q2 2023 earnings were reported, revealing a mix of improvements and declines.
GoHealth reported a decrease in net revenues but an improvement in net loss and Adjusted EBITDA for Q2 2023. The company is updating its full year 2023 outlook and expects total net revenue of $800 - $850 million and Adjusted EBITDA of $120 - $140 million, both excluding non-Encompass BPO Services.
- Net revenues decreased to $142.8 million compared to the prior year period.
- Submissions increased by 5% compared to the prior year period.
- Net loss improved to $70.2 million compared to the prior year period.
- Adjusted EBITDA improved to $0.8 million compared to the prior year period.
Headline financials
Revenue & EPS history
GoHealth · Revenue · Quarterly
$143M
Revenue by segment
GoHealth · $11.9M total across 4 segments · Q1 2026
- Medicare Agency Revenue$9.8M—82.2%
- Other Non-Agency Revenue$1.76M—14.8%
- Medicare Non-Agency Revenue$200K—1.7%
- Other Agency Revenue$155K—1.3%
Forward guidance
The Company updates its full year 2023 outlook and expects total net revenue of $800 - $850 million and Adjusted EBITDA of $120 - $140 million, both excluding non-Encompass BPO Services. The Company also expects positive cash flow from operations of $75 - $115 million.
Tailwinds
- Total net revenue expected to be $800 - $850 million (excluding non-Encompass BPO Services).
- Adjusted EBITDA expected to be $120 - $140 million (excluding non-Encompass BPO Services).
- Positive cash flow from operations expected to be $75 - $115 million.
- Guidance updates reflect increases to the lower bounds previously communicated for total net revenue and Adjusted EBITDA ranges.
- Company is committed to enhancing the consumer experience through Encompass.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
-7.7%
Avg return
Earnings day
-9.7%
Avg return
5 days after
-6.6%
Avg return
30 days after
26%
6 / 23 earnings
Positive
+32.2%
Q1 2023
Best reaction
-45.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.5% | -23.4% | — | |
| Q3 2025 | -24.4% | -32.0% | -12.8% | |
| Q2 2025 | -9.0% | -7.6% | -23.8% | |
| Q1 2025 | -0.6% | -17.4% | -21.4% | |
| Q4 2024 | -14.4% | -14.9% | -32.8% | |
| Q3 2024 | -6.6% | -0.4% | -15.4% | |
| Q2 2024 | -21.4% | -28.3% | -34.0% | |
| Q1 2024 | -8.0% | -11.1% | +2.2% | |
| Q4 2023 | -13.0% | -25.7% | -27.0% | |
| Q3 2023 | +2.3% | +6.7% | +7.4% | |
| Q2 2023 | +6.8% | +6.3% | -17.2% | |
| Q1 2023 | +32.2% | +44.8% | +99.5% | |
| Q4 2022 | -19.9% | -6.2% | -18.5% | |
| Q3 2022 | -16.7% | -9.4% | +95.3% | |
| Q2 2022 | -31.5% | -43.3% | -57.0% | |
| Q1 2022 | +11.1% | +4.9% | +6.5% | |
| Q4 2021 | +23.7% | +37.7% | -9.8% | |
| Q3 2021 | +1.1% | -4.7% | -18.1% | |
| Q2 2021 | -45.5% | -42.2% | -34.7% | |
| Q1 2021 | -2.7% | -5.6% | -4.0% | |
| Q4 2020 | -14.9% | -16.9% | -4.1% | |
| Q3 2020 | -14.9% | -15.1% | +1.8% | |
| Q2 2020 | -10.5% | -18.5% | -27.1% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro